Animals can be induced to resist cochlear damage associated with acoustic trauma by exposure to a variety of "conditioning" stimuli, including restraint stress, moderate level sound, heat stress, hypoxia, and corticosteroids. Here we identify in mice a corticosteroidresponsive transcription factor, PLZF (promyelocytic leukemia zinc finger protein), which mediates conditioned protection of the cochlea from acoustic trauma. PLZF mRNA levels in the cochlea are increased following conditioning stimuli, including restraint stress, dexamethasone administration, and moderate-to-high level acoustic stimulation. Heterozygous mutant (luxoid.Zbtb16 LU /J) mice deficient in PLZF have hearing and responses to acoustic trauma similar to their wild type littermates but are unable to generate conditioninginduced protection from acoustic trauma. PLZF immunoreactivity is present in the spiral ganglion, lateral wall of the cochlea, and organ of Corti, all targets for acoustic trauma. PLZF is also present in the brain and PLZF mRNA in brain is elevated following conditioning stimuli. The identification of a transcription factor that mediates conditioned protection from trauma provides a tool for understanding the protective action of corticosteroids, which are widely used in treating acute hearing loss, and has relevance to understanding the role of corticosteroids in trauma protection.
Introduction
Exposure to very loud sounds can produce permanent hearing loss by irreplaceably damaging the sensory cells (hair cells) and auditory neurons in the cochlea. It has been known for decades that the cochlea can be conditioned to resist damage by prior exposure to moderate-level sounds (Miller et al., 1963; Canlon et al., 1988) . The amount of protection is remarkable: up to 30 dB of permanent hearing loss can be prevented. The mechanism by which this protection is created is not understood. Some insight into this enigmatic phenomenon has come from experiments indicating that protection can also be induced by stress, including heat stress (Yoshida et al., 1999) and restraint stress , presumably via a corticosteroid-dependent process (Tahera et al., 2006a,b) .
Here we identify a corticosteroid-responsive transcription protein, PLZF (promyelocytic leukemia zinc finger protein), which is essential to mediate cochlear protection. PLZF is a transcription suppressor in the family of Kruppel-type zinc finger proteins and contains a conserved POZ protein-binding domain at its N terminus. PLZF expression is corticosteroid responsive (Fahnenstich et al., 2003; Wasim et al., 2010) , is expressed in the inner ear (Nagy et al., 2005) , and has been identified as an interaction partner with prestin (Nagy et al., 2005) , a cochlear motor protein responsible for amplifying acoustic input to the cochlea (Zheng et al., 2000) . Thus PLZF is a reasonable candidate to mediate conditioning-induced protection in the cochlea.
We demonstrate that PLZF mRNA is elevated in the mouse cochlea (and brain) following restraint stress. We show it is present in the spiral ganglion, organ of Corti, and stria vascularis, all targets for acoustic trauma. Importantly, mutant mice deficient in PLZF have hearing similar to their wild-type littermates, but are unable to generate conditioning-induced protection from acoustic trauma. Finally, corticosteroid (dexamethasone) given either before or after noise exposure can also induce PLZF expression and protection.
The identification of a transcription factor that mediates protection from trauma provides a tool for understanding the protective action of corticosteroids, which are widely used in treating acute hearing loss (Rauch et al., 2000) . PLZF is widely expressed in brain and in other tissues, leading to the possibility that our findings may be generalizable to other forms of conditioned protection and may have relevance to understanding the role of corticosteroids in trauma protection in general.
drop to much lower levels at 10 -12 weeks (see Fig. 2a, below) , a time when B6 mice are beginning to show some hearing loss. So PLZF mRNA levels in response to conditioning stimuli were made on CB mice at 10 -12 weeks, when background PLZF mRNA levels were low.
Luxoid (PLZF-deficient) breeding pairs from cryopreserved (B6.C3-Zbtb16 LU /J, # 000100) stock were obtained from The Jackson Laboratory. This mouse, first recognized in 1955 (Green, 1955) , has a point mutation in the PLZF gene resulting in an attenuated protein missing the zinc finger (DNA binding) domain (Buaas et al., 2004) . Progeny were genotyped by Transnetyx Inc. using a quantitative PCR (qPCR)-based system and a Zbtb16 -1 MU probe able to detect the point mutation in the codon 234 that transforms an Arg codon in a nonsense codon in the luxoid mouse.
For this study we have used 86 mixed male and female B6.C3-Zbtb16Lu/J 6-week-old mice,. Age-and gender-matched wild-type cage mates of the PLZF mutants, treated identically, served as controls. We also used 197 CB mice obtained from The Jackson Laboratory or from a colony established from those mice. All procedures were approved by the Institutional Animal Care and Use Committee of the Massachusetts Eye and Ear Infirmary.
Immunolocalization of PLZF. To examine the distribution of PLZF in the cochlea, mid-modiolar paraffin sections were prepared from both cochleae of ϩ/ϩ unrestrained (4 mice), ϩ/ϩ restrained (3 mice), and Ϫ/Ϫ unrestrained (3 mice) 10-to 12-week-old B6 animals (10 mice for a total of 20 cochleae). After intracardiac perfusion with 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4, cochleas were perfused with Bouin's solution (Sigma), fixed overnight, decalcified for 12 h in 0.5 M ETDA, dehydrated through alcohol over 24 h, and embedded in paraffin. Sections (10 m) were dewaxed in xylene, rehydrated through alcohol into PBS, incubated overnight in 10% goat serum, and labeled with primary antibodies to PLZF overnight [Abcam ab39354, targeting a region between amino acid 650 and the C terminus of PLZF protein, dilution 1:1000; Santa Cruz Biotechnology #SC28319 (anti-mouse PLZF d9; dilution 1:300)], placed for 1 h in anti mouse secondary antibody (Invitrogen Alexa Fluor 647 anti-mouse (dilution 1:500). Two different antibodies to PLZF were used to document its distribution. The images above were from the Abcam PLZF antibody, which showed very little nonspecific label. Data (data not shown) were also obtained with a Santa Cruz Biotechnology antibody, which indicated specific label [based on comparison to PLZF (Ϫ/Ϫ) mice] in pillar cells and type 3 fibrocytes, but nonspecific label in the nuclei of the spiral ganglion cells.
Real-time quantitative PCR of cochlea and brain. Real-time quantitative PCR (RT-PCR) was used to assess PLZF mRNA levels in the cochlea and brain. For each sample, the spiral ganglion and organ of Corti from both ears of CB mice were pooled and dissected in RNA later (Ambion), homogenized in 1 ml of TRIzol, and centrifuged after adding 200 l of chloroform. Supernatant (700 l) was collected and purified using RNeasy spin-columns (Qiagen). The reverse transcription reaction included: 40 l of cDNA, 11 l of 50 mM MgCl2, 20 l of dNTP mix, 5 l of 2.5 M random primer (Invitrogen) and 1 l of superscript II (Invitrogen), incubated in a PTC-100 programmable thermal controller (MJ Research, Inc). Real time amplification used a Platinum qPCR super mix-UDG with ROX (Invitrogen) and a probe for mouse PLZF (Applied Biosystems, Mn001176866_m1 Zbtb16). 18S rRNA (Applied Biosystems, HS99999901-S1) was used as an internal control. Real time quantification was accomplished with one of two systems: a Stratagene MX3005P or [in earlier experiments (see Fig. 2a , below; supplemental Fig. 2 , available at www.jneurosci.org as supplemental material)] an ABI Prism 7700 sequence Detector (PerkinElmer). Because the run and analysis algorithms of the two systems were different, we are hesitant to compare data across the two systems. Thirty-six CB embryos (mixed male and female) from 11 pregnant CB mice were used to analyze developmental changes in PLZF mRNA. CB mice were used for brain (n ϭ 30) and cochlear (n ϭ 36) expression of PLZF following restraint stress. Twenty-six CB mice were used to compare mRNA expression with restraint stress, acoustic trauma, and dexamethasone.
Western blot analysis of PLZF. To measure protein levels in the PLZF mutants, we also performed Western blot analysis of PLZF expression in ϩ/ϩ, ϩ/Ϫ, and Ϫ/Ϫ luxoid mutants (supplemental Fig. 3 , available at www.jneurosci.org as supplemental material). For each sample, half of the brain from ϩ/ϩ, ϩ/Ϫ, and Ϫ/Ϫ littermates was collected and placed in 600 l of radioimmunoprecipitation buffer (150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) with protease inhibitor (dilution 1:100) and homogenized. After centrifugation at 15,000 ϫ g at 4°C for 15 min, the supernatant was collected and boiled for 5 min at 100°C. A total of 30 l of each protein sample was mixed with Laemmli sample buffer (Bio-Rad Laboratories) and loaded on a 7.5% Tris-HCl gel and then electrophoretically transferred to a PVDF membrane. The membrane was blocked with 10% dry milk in TBST (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. The membrane was incubated with mouse anti-PLZF (D-9): sc-28319 (Santa Cruz Biotechnology; dilution 1:1000) in 1% milk in TBST at 4°C overnight. After washing with TBST, the membrane was incubated with an anti-mouse HRP for 1 h. The membrane was washed in TBST and the blots were developed by incubating the membranes with SuperSignal West Pico chemiluminescent substrate (Pierce) for 5 min. Measurement of ␤ actin served as an indicant of the amount of tissue applied to each lane. To measure ␤ actin, the membrane was stripped for 10 min at room temperature with Restore Western blot stripping buffer (Thermo Scientific 21059), and incubated overnight with a mouse anti B-actin antibody (1:1000) and anti-mouse HRP (1:20.000) as described above.
Restraint stress. Restraint stress was used to induce cochlear protection from acoustic trauma. The technique is simple, reliable and can induce protection within 12 h Tahera et al., 2006b) . Restraint stress was generated by restraining mice in 50 ml (3 by 11 cm) ventilated (5 mm distributed holes) centrifuge tubes. A total of 24 B6.C3-Zbtb16
Lu /J, aged 6 weeks (18 -25 g), were analyzed. Each mouse was subjected to a single 12 h period of restraint in the ventilated tube immediately followed by a 2 h period of acoustic noise exposure (see below). After the exposure, animals were returned to the animal care facility for later monitoring of threshold shift. In preliminary experiments with 25 CB mice, thresholds were measured in one of the ears at 3 d, 7 d, and 14 d after the noise exposure. In these animals, threshold shifts were highest at 3 d, with lower shifts at 7 and 14 d. Because shifts were similar at 7 and 14 d, we chose 7 d after the exposure to assess threshold shift in auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAEs).
Acoustic overexposures. Acoustic overexposures were used to generate cochlear damage. The acoustic stimulus was an octave band of noise (8 -16 kHz) delivered at 100 dB SPL, for 2 h. Exposures were delivered to awake mice restrained within small cells in a subdivided cage (1 animal/ cell). The cage was placed directly below the horn of the sound-delivery loudspeaker in rotating platform in a small, reverberant chamber. Noise calibration to target the sound pressure level was performed immediately before each exposure session. Sound pressure levels varied by Ͻ1 dB across the cells. In a small subset of experiments, mice were exposed to either 88 or 102 dB SPL for 2 h to determine the effects of higher-level acoustic overexposure on PLZF levels.
Dexamethasone administration. Dexamethasone sodium phosphate (American Regent, Inc) at 4 mg/ml was diluted to 0.25 mg/ml with saline, and delivered intraperitoneally at doses of 0.005, 0.05, 0.15, 0.5, 1.5, and 5 mg/kg. Intraperitoneal administration of 0.5 ml of saline served as a control. Each dose was administered to three to seven 12-week-old CB mice (total ϭ 46 mice). Dexamethasone was delivered either immediately before or immediately after the acoustic overexposure (see above). DPOAE and ABR thresholds were measured 7 d later. In 4 CB mice, 0.5 mg/kg dexamethasone was administered and the mice killed 3 h later for analysis of PLZF mRNA levels.
Physiological tests. Mice were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Acoustic stimuli (5.6 -45 kHz) were delivered via a custom acoustic assembly consisting of two electrostatic drivers as sound sources (EC-1, Tucker Davis Technologies) and a miniature electret microphone to measure sound pressure in situ. ABRs were recorded via subdermal needle electrodes (vertex-ventrolateral to the pinna of the test ear with a ground at the base of the tail). The response from the electrodes was amplified (10,000x), filtered (0.1-3 kHz bandpass), and averaged (512 samples at each frequency-level combination).
Sound level was incremented in 5 dB steps, from ϳ10 dB below threshold to 90 dB SPL. Threshold for ABR was defined as the lowest stimulus level at which a repeatable wave could be identified in the response waveform. DPOAEs were recorded for primary tones (f1, f2) over the same f2 range of frequencies, with a frequency ratio of 1.2, and with the level of the f2 primary 10 dB less than f1 level. Primaries were incremented together in 5 dB steps from ϳ10 dB below threshold to 80 dB SPL. Ear-canal sound pressure was amplified and digitally sampled, fast Fourier transforms were computed and averaged, and the 2f1-f2 DPOAE and surrounding noise floor were extracted. Iso-response contours were interpolated from plots of response amplitude vs sound level. "Threshold" is defined as the f1 level required to produce a DPOAE of Ϫ5 dB SPL. In each animal, we looked only at the response from the right ear. Threshold contours were compared and statistically analyzed with a two-way ANOVA.
Results

Both restraint stress and corticosteroids can induce protection from acoustic trauma
We used restraint stress to induce cochlear protection from acoustic trauma. To measure protection, we exposed mice to a 2 h period of 100 dB SPL (8 -16 kHz) noise in the presence and absence of restraint stress (Fig. 1) . Noise alone induced threshold elevations, measured 7 d later, of ϳ30 -40 dB, indicating permanent threshold shift. When restraint stress was administered immediately before this same noise exposure, hearing loss was much smaller; generally Ͻ10 dB of threshold shift was observed.
We compared the protective effects of restraint stress to those of the corticosteroid, dexamethasone (0.5 mg/kg, i.p.), administered either immediately before or after noise exposure (Fig. 1) . Dexamethasone provided an amount of protection similar to restraint stress. Importantly, the amount of protection was the same whether the dexamethasone was administered before or after the trauma, indicating that the protective mechanism does not involve an attenuation of the physical input to the inner ear. The effects of dexamethasone were sharply dependent on dose: 0.5 and 1.5 mg/kg produced protection similar as that illustrated in Figure 1 (ϳ30 dB at 16 and 22 kHz), but the effects at 0.15 or 5 mg/kg were similar to those with saline, which afforded a small amount (ϳ15 dB) protection, possibly due to stress of the intraperitoneal injection itself.
Restraint stress, corticosteroids, and acoustic stimulation reversibly increased PLZF mRNA levels We determined whether restraint stress or dexamethasone could induce production of PLZF by measuring PLZF mRNA using quantitative, real-time PCR. We first analyzed levels of PLZF mRNA as a function of mouse age (Fig. 2a) . This indicated endogenous cochlear levels were highest around postnatal day 30 (P30) and dropped considerably by P90. We used P90 mice for subsequent analyses to take advantage of their lower background levels of PLZF. Restraint stress reversibly increased PLZF mRNA in both the cochlea and the brain (Fig. 2b) , with peak levels observed between 4 and 8 h of restraint. Dexamethasone (0.5 mg/kg, i.p.) elevated cochlear PLZF mRNA around fivefold (4.84 Ϯ 0.83; mean Ϯ SE; n ϭ 4 mice; p ϭ 0.018 by Student's unpaired t test), measured 3 h after a single injection (data not shown).
We also evaluated changes in PLZF mRNA following acoustic overexposure. Mice were confined in the exposure chamber and exposed to 2 h of 8-16 kHz noise at 88 or 102 dB SPL, or were simply confined to the chamber for 2 h. PLZF mRNA was measured 2 h after the exposure (supplemental Fig. 2 , available at www.jneurosci. org as supplemental material). Acoustic overexposure produced elevations in PLZF. However, simply confining the animal in the exposure chamber also-evoked elevations in PLZF mRNA. Restraint stress was performed on 6-week-old B6 mice, the background strain for the luxoid mutant (see Fig. 4 ). Dexamethasone experiments were performed on 10-to 12-week-old CB mice. Threshold shifts were obtained by subtracting thresholds following noise exposure from those of unexposed animals. Noise-only shifts for 6 week B6 and 10 -12 week CB were similar and were combined here for display purposes. Individual plots for dexamethasone effects in CB mice and restraint stress effects in B6 mice are presented as supplemental Figure 1 (available at www.jneurosci.org as supplemental material). 
PLZF immunolabel is present in the cochlea
We determined the cellular distribution of PLZF using immunohistochemistry in the adult cochlea. PLZF immunoreactivity (Fig. 3) was highest in the cochlear nerve, the pillar cells of the organ of Corti, and in basal cells of the stria vascularis, but was widely distributed throughout the cochlea (Fig. 3a,b) . Homozygous mutant controls (PLZF Ϫ/Ϫ) mice-see below) showed no immunolabel with PLZF antibody (Fig. 3c) . PLZF label in the auditory nerve (Fig. 3f ) appeared primarily in the Schwann cells: label terminated centrally at the Schwann cell-glial cell (CNS) border and terminated peripherally at the habenula perforata, where the auditory neurons become unmyelinated. Neuronal cell bodies were also labeled, though not as strongly. The stria vascularis was more strongly labeled than the surrounding tissue, and within the stria, labeling was strongest in the basal cells (Fig. 3d) . Within the organ of Corti (Fig. 3e) , label was often very strong in the heads and feet of the pillar cells, but was also present in the hair cells and supporting (Deiter's) cells (see also Nagy et al., 2005) . To determine whether restraint stress altered PLZF distribution, we exposed mice to restraint stress and immunolabeled the cochlea with antibodies to PLZF. Immunoreactivity was increased and generally distributed among the same cells expressing PLZF in the absence of restraint stress (compare Fig. 3a,b) .
We examined the auditory phenotype of PLZF-deficient mice
To determine whether the increases we observed in PLZF following restraint stress were essential to induce protection, we established a breeding colony from cryopreserved luxoid mice obtained from The Jackson Laboratory. This mouse has a point mutation in the PLZF gene resulting in an attenuated protein missing the zinc finger (DNA binding) domain (Buaas et al., 2004) . PLZF-deficient homozygotes (Ϫ/Ϫ) exhibit polydactyly, mild hindlimb abnormalities, fusion of vertebrae, and spermatogonia dysfunction (Green, 1955; Barna et al., 2000; Buaas et al., 2004; Ching et al., 2010) . The auditory phenotype of this mouse has not been previously described, so we describe it here. We observed no gross histological defects in the cochlea. We studied cochlear function across a broad range of frequencies (5.6 -45 kHz) using two physiological measures: (1) DPOAEs, which reflect cochlear outer hair cell function and (2) ABRs, which represent the summed activity of the auditory nerve. In 4-week-old Ϫ/Ϫ mice, ABR and DPOAE thresholds to acoustic stimulation were slightly poorer (ϳ10 dB) than those of wild-type mice (data not shown). Heterozygotes (ϩ/Ϫ) of the same age had normal ABR and DPOAE responses. By 6 weeks, Ϫ/Ϫmice had ABR and DPOAE threshold elevations of 15-30 dB (Fig. 4) and prolonged (0.2 ms) wave 1 latencies relative to wild types, while ϩ/Ϫ mice maintained nearly normal responses.
PLZF-deficient mice cannot induce protection from acoustic trauma with restraint stress
Since elevations of baseline threshold can reduce noise-induced threshold shift, to assess the role of PLZF in conditioning we studied PLZF heterozygotes, with nearly normal baseline thresholds but only half the normal protein (supplemental Fig 3, available at www.jneurosci.org as supplemental material). Unconditioned (no restraint stress) PLZF (ϩ/Ϫ) mice and their wild-type littermates showed similar vulnerability to acoustic (e), and spiral ganglion (f ) are presented. Strongest label is observed in the auditory nerve, in heads of the pillar cells (pc), and in basal cells (bc) of the stria vascularis (sv), but label is widely distributed throughout the cochlea, including: sv, fibrocytes of the spiral ligament (sl), and blood vessels (bv); the phalangeal processes of Dieter's cells, inner hair cells (ihc), and outer hair cells (ohc) of the organ of Corti (oc) (see also Nagy et al., 2005) ; and neuronal cell bodies of the spiral ganglion neuron, where punctate label in the cytoplasm is evident. Observations were made on both cochleae from 6 wild-type and 4 homozygous mutant mice.
overexposure at the frequency regions of maximum shift (30 -40 dB). Shifts persisted for both groups at 15 d postexposure (data not shown) indicating permanent threshold shifts. Restraint stress, applied immediately before acoustic overstimulation, provided nearly complete protection in wild-types (Fig. 5a,c) : ABR thresholds 7 d after exposure were elevated only 5-10 dB. This protective effect was also seen in DPOAE thresholds (Fig. 5c) . In contrast, in PLZF-deficient (ϩ/Ϫ) mice, restraint stress failed to provide protection from overexposure (Fig. 5b,d ): threshold shifts were as large as in the un-conditioned group.
Discussion
Our findings indicate that PLZF, a corticosteroid-responsive transcription protein, is a strong candidate to mediate conditioning-induced protection of the cochlea from acoustic trauma. The central finding supporting this hypothesis is that mice deficient in PLZF are unable to generate protection with restraint stress. Additional support comes from our observation that PLZF mRNA levels are increased in the cochlea following stimuli that induce conditioning, including restraint stress, dexamethasone, and acoustic overexposure. Finally, PLZF immunoreactivity is present in the cochlea including the spiral ganglion, the lateral wall, and, as previously noted (Nagy et al., 2005) , the organ of Corti, all targets for acoustic trauma . Our observation that dexamethasone induced similar amounts of protection whether administered before or after the acoustic trauma suggests that the protective effects associated with PLZF are not simply due to attenuating the mechanical stimulus to the organ of Corti, but may involve either attenuation of a damage process that occurs following the stimulus, repair of damage suffered during the acoustic trauma, or both. This opens the possibility that the protective pathways induced by PLZF may be generalizable to understanding other therapeutic actions of corticosteroids.
Organisms have developed several means of protecting the cochlea from acoustic overstimulation Middle ear muscle contraction and activation of olivocochlear efferent pathways effectively attenuate the stimulus presented to the organ of Corti with a time course measured in ms. Conditioning-induced protection is interesting because it appears to involve some "metabolic" process requiring hours to develop. The phenomenon of conditioning originally referred to protection induced by preexposure to moderate-level (nontraumatic) sound (Canlon et al., 1988; Campo et al., 1991; Ryan et al., 1994; Niu and Canlon, 2002) , but a variety of stimuli have been found to induce conditioning, including restraint stress Tahera et al., 2006b ), heat stress (Yoshida et al., 1999) , sham surgery (Kujawa and Liberman, 1997) , corticosteroids (Takemura et al., 2004; Tabuchi et al., 2006; Tahera et al., 2006b) , kanamycin (Fernandez et al., 2010) , and hypoxia (Gagnon et al., 2007) . Indeed, suggested that it is the stress that results from exposure to the acoustic conditioning procedure, rather than the acoustic signal itself, that may underlie the protection. This suggestion is supported by our observation that simply restraining the animal in the acoustic exposure chamber produced increases in PLZF mRNA similar to those in response to a moderate level (88 dB SPL) sound classically used to evoke conditioning (Yoshida and Liberman, 2000) . Our observation that cochlear PLZF mRNA levels are increased by exposure to moderate-to high-level acoustic stimulation suggests that this putative protective mechanism is evoked during traumatic acoustic exposure, though the amount of protection evoked may be small based on our observation that wildtype and PLZF (ϩ/Ϫ) mice respond similarly to acoustic overexposure at the frequencies of maximum threshold shift. There is obviously additional protection associated with prior exposure to restraint stress or concomitant exposure to dexamethasone (Figs. 1, 5) . As yet unexplored are a number of factors in the relation between PLZF elevation and protection. For example, questions such as how long must PLZF be elevated and what is the relationship between PLZF elevation and the time of optimal protection are not answered. In addition, the possibility that other factors also play a role in generating protection must be considered. Our work demonstrates that PLZF is necessary to generate protection by restraint stress, but does not show whether or not is sufficient.
Glucocorticoid receptor activation may mediate several forms of protection from acoustic overexposure Restraint stress evokes corticosteroid release from the adrenal gland (Curtis and Rarey, 1995) and Canlon and colleagues (Tahera et al., 2006b ) present evidence that restraint stress provides protection via a corticosteroid mediator. Corticosteroid release is evoked by other conditioning stimuli such as hypoxia (Raff et al., 1983) and heat stress (Djordjević et al., 2003) . Synthetic corticosteroids such as methylprednisolone (Takahashi et al., 1996) and dexamethasone (Takemura et al., 2004; Tahera et al., 2006a) can induce protection from threshold shift associated with high level sound. PLZF production is increased in response to corticosteroids, but is also increased in response to a variety of other stimuli, including aldosterone, progesterone and androgens (Jiang and Wang, 2004; Náray-Fejes-Tó th et al., 2008) . Thus it plausible non-corticosteroidal mechanisms may also be at play in evoking PLZF-induced protection.
Mechanisms of PLZF-induced protection
While activation of corticosteroid receptors often results in DNA binding of the receptor-ligand complex and subsequent alteration in gene expression (Giguère et al., 1986) , a non-genomic action of corticosteroids on PLZF expression has been implicated in an analysis of endometrial stromal cells (Fahnenstich et al., 2003) . The cytosolic localization of PLZF both in the control and restrained mice suggests it may be binding and recruiting cytosolic protein targets to the nucleus, as has been demonstrated for its interaction with epsin (Hyman et al., 2000) and with the G-protein coupled angiotensin II receptor (Senbonmatsu et al., 2003) . In that regard, PLZF has been shown to be an interaction partner with prestin (Nagy et al., 2005) , the major protein functioning as the cochlear amplifier in the outer hair cell (Zheng et al., 2000) . Both espin and prestin appear to bind to the same region of PLZF (at the first of nine zinc finger domains near the C terminus), leading Nagy et al. (2005) to suggest a similar interaction between PLZF and prestin.
The acoustic exposure we used (100 dB SPL, 8 -16 kHz for 2 h) was identical to that used by to correlate histological changes to physiological changes in 10-week-old CB mice. Their conclusion was that the PTS correlated to stereociliary damage when the sound exposure was lower than that which produced frank rupture of the reticular lamina. For the exposure we used, the most likely correlate would be damage to the outer hair cell stereocilia.
Maintenance of cochlear stereocilia appears to be a very dynamic process with association and disassociation of actin filaments under active control (Rzadzinska et al., 2004; Belyantseva et al., 2009; Peng et al., 2009; Herde et al., 2010; Zheng et al., 2010) . Stereocilia damage becomes more severe with increasing time or intensity of acoustic exposure, a finding that might be interpreted as an inability of these dynamic processes to keep up with an increased demand associated with acoustic overstimulation. Dexamethasone provided protection from PTS in similar amounts whether given before or after the acoustic overexposure, implying that protection is not attenuating the stimulus input in any way, but involves either attenuation of a damage process that occurs following the stimulus or repair of damage suffered during the acoustic trauma (or both).
Corticosteroids are, at present, one of the few available treatments for acute loss of hearing, and their mechanisms of action are not understood (Rauch et al., 2000; Schreiber et al., 2010) . While many promising potential targets of steroid activation have been analyzed in the ear (Tahera et al., 2006a; Haake et al., 2009) , no compelling mechanism has yet been identified for its action. We raise the possibility that PLZF elevation represents one component, of the broad spectrum of corticosteroid actions, which may be responsible for cochlear protection. The spectrum of damage produced in acoustic trauma overlaps the spectrum of loss with other forms of degenerative sensorineural hearing loss, ranging from strial and ligament pathology to hair cell and spiral ganglion neuron loss . It is possible that protective mechanisms in acoustic trauma are shared with those for other modes of cochlear injury and degeneration.
It is plausible that PLZF is responsible for protective effects of corticosteroids in the brain and spinal cord PLZF is present in the brain and is elevated following restraint stress with a similar time course to the changes we observe in the cochlea (Fig. 2) . Corticosteroids have some beneficial therapeutic actions in brain and spinal cord trauma, though the complex array of actions associated with these agents limit their clinical usefulness (Roberts et al., 2004) . Our identification of a single, corticosteroid-responsive transcription factor that is essential to induce conditioning-mediated protection from acoustic trauma offers a straightforward opportunity to identify specific molecular mechanisms that protect and repair the cochlea. One can speculate that there is a steroid-responsive molecular pathway involved in protection and prevention of cochlear degeneration following acoustic trauma that may prove useful in treating other forms of hearing loss or brain injury.
